Oramed Pharmaceuticals (FRA:OJU1) EPS (Basic) : €0.24 (TTM As of Mar. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Oramed Pharmaceuticals EPS (Basic)?

Oramed Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Mar. 2024 was €0.04. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2024 was €0.24.

Oramed Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2024 was €0.04. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €0.24.

Oramed Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2024 was €0.04. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was 0.24.

During the past 3 years, the average EPS without NRI Growth Rate was 21.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was 13.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 2.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Oramed Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 21.50% per year. The lowest was -188.40% per year. And the median was -1.60% per year.

Oramed Pharmaceuticals EPS (Basic) Historical Data

The historical data trend for Oramed Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oramed Pharmaceuticals EPS (Basic) Chart

Oramed Pharmaceuticals Annual Data

Trend

Aug14

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-0.74

-0.47

-0.66

-0.89

0.13

Oramed Pharmaceuticals Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EPS (Basic)	Get a 7-Day Free Trial															-0.08	-0.03	-0.08	0.30	0.04

Oramed Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Oramed Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(5.066	-	0)	/	40.315
	=	0.13

Oramed Pharmaceuticals's Basic EPS for the quarter that ended in Mar. 2024 is calculated as

Basic EPS (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(1.413	-	0)	/	40.836
	=	0.03

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.24

Oramed Pharmaceuticals (FRA:OJU1) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Oramed Pharmaceuticals EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Oramed Pharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Oramed Pharmaceuticals (FRA:OJU1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oramed Pharmaceuticals Inc (FRA:OJU1) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

ORMP:USA

Address

1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036

Website

https://www.oramed.com

Oramed Pharmaceuticals Inc is a pharmaceutical company which is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The ORMD-0801 is a proprietary product which is an orally ingestible insulin capsule for the treatment of diabetes. Its other product includes Oral Glucagon-like peptide-1 which is an incretin hormone, a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas.

Oramed Pharmaceuticals (FRA:OJU1) Headlines

No Headlines